Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
- Conditions
- Cognitive/Functional EffectsColorectal CancerNeurotoxicity
- Interventions
- Biological: bevacizumabDrug: capecitabineDrug: fluorouracilDrug: leucovorin calciumDrug: oxaliplatin
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 32
- Registration Number
- NCT01279681
Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer
- Conditions
- Rectal Tumour
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT01273051
- Locations
- 🇳🇱
Academisch Medisch Centrum, Amsterdam, Netherlands
🇳🇱Slotervaart Ziekenhuis, Amsterdam, Netherlands
🇳🇱Amphia Ziekenhuis, Breda, Netherlands
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT01268943
- Locations
- 🇨🇳
radiation department, Cancer Hospital, CAMS, Beijing, Beijing, China
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
- Conditions
- Stage IVA Oral Cavity Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Hypopharyngeal Squamous Cell CarcinomaStage IVB Laryngeal Squamous Cell CarcinomaStage IVB Oral Cavity Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT01267240
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2011-03-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 516
- Registration Number
- NCT01249638
- Locations
- 🇩🇪
University of Munich - Klinikum der Universitaet Muenchen, Munich, Germany
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
- Conditions
- Hepatic Neoplasm Malignant
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Sanofi
- Registration Number
- NCT01245582
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT01234402
- Locations
- 🇨🇦
ImClone Investigational Site, Toronto, Ontario, Canada
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 537
- Registration Number
- NCT01234337
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
- Conditions
- Adenocarcinoma of the PancreasAdenocarcinoma of the StomachBRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Mucinous CystadenocarcinomaRecurrent Breast CancerRecurrent Colon CancerRecurrent Rectal CancerStage IIIA Breast CancerRecurrent Gastric Cancer
- Interventions
- Drug: veliparibDrug: capecitabineDrug: oxaliplatinOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT01233505
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Adherex Technologies, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT01231802
- Locations
- 🇷🇺
Chelyabinsk Regional Clinical Oncology, Chelyabinsk, Russian Federation
🇷🇺Republic Oncology Center, Republic of Karelia, Russian Federation
🇷🇺Stavropol Regional Clinical Oncology Center, Stavropol, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.